CHAPTER 11
|
Juvenile Idiopathic Arthritis
367
113. Silber T, Majd M. Reflex sympathetic dystrophy syndrome in children
and adolescents. Report of 18 cases and review of the literature.
Am J Dis
Child
1988;142:1325.
114. Sherry D, Weisman R. Psychologic aspects of childhood reflex neurovas-
cular dystrophy.
Pediatrics
1988;81:572.
115. Ladd J, Cassidy J, Martel W. Juvenile ankylosing spondylitis.
Arthritis
Rheum
1971;14:579.
116. Rahimtoola Z, Finger S, Imrie S. Outcome of total hip arthroplasty in
small-proportioned patients.
J Arthroplasty
2000;15(1):27.
117. Senac M, Deutsch D, Bernstein B. MR imaging in juvenile rheumatoid
arthritis.
AJR Am J Roentgenol
1988;150:873.
118. Verbruggen L, Shahabpour M, Roy PV. Magnetic resonance imaging of
articular destruction in juvenile rheumatoid arthritis.
Arthritis Rheum
1990;33:1426.
119. Yulish B, Lieberman J, Newman A. Juvenile rheumatoid arthritis: assess-
ment with MR imaging.
Radiology
1987;165:149.
120. Cabral D, Petty R, Fung M. Persistent antinuclear antibodies in children
without identifiable inflammatory, rheumatic or autoimmune disease.
Pediatrics
1992;89:441.
121. Allen R, Dewez P, Stuart L. Antinuclear antibodies using HEp-2 cells
in normal children and in children with common infections.
J Paediatr
Child Health
1991;27:39.
122. Deane P, Liard G, Siegel D. The outcome of children referred to a pedi-
atric rheumatology clinic with a positive antinuclear antibody test but
without an autoimmune disease.
Pediatrics
1995;95:892.
123. Rosenberg A. Uveitis associated with juvenile rheumatoid arthritis.
Semin Arthritis Rheum
1987;16:158.
124. Stillman J, Barry P. Juvenile rheumatoid arthritis: series 2.
Arthritis
Rheum
1977;20:171.
125. Schaller J. Juvenile rheumatoid arthritis: series 1.
Arthritis Rheum
1977;
20:165.
126. Schellekens GA, et al. The diagnostic properties of rheumatoid arthri-
tis antibodies recognizing a cyclic citrullinated peptide.
Arthritis Rheum
2000;43(1):155–163.
127. Kroot EJ, et al. The prognostic value of anti-cyclic citrullinated peptide
antibody in patients with recent-onset rheumatoid arthritis.
Arthritis
Rheum
2000;43(8):1831–1835.
128. van Jaarsveld CH, et al. The prognostic value of the antiperinuclear fac-
tor, anti-citrullinated peptide antibodies and rheumatoid factor in early
rheumatoid arthritis.
Clin Exp Rheumatol
1999;17(6):689–697.
129. Petty R. HLA-B27 and rheumatic diseases of childhood.
J Rheumatol
1990;17:7.
130. Cassidy J, Brody G, Martel W. Monoarticular juvenile rheumatoid
arthritis.
J Pediatr
1967;70:867.
131. Baldassare A, Chang F, Zuckner J. Markedly raised synovial fluid leu-
kocyte counts not associated with infectious arthritis in children.
Ann
Rheum Dis
1978;37:404.
132. Zuckner J, Baldassare A, Chang F. High synovial fluid leukocyte counts
of noninfectious etiology.
Arthritis Rheum
1977;20:270.
133. Vane J. Inhibition of prostaglandin synthesis as a mechanism of action
for aspirin-like drugs.
Nat New Biol
1971;231:232.
134. Lindsley C. Uses of nonsteroidal anti-inflammatory drugs in pediatrics.
Am J Dis Child
1993;147:229.
135. Mulberg A, Linz C, Bern E. Identification of nonsteroidal antiinflam-
matory drug-induced gastroduodenal injury in children with juvenile
rheumatoid arthritis.
J Pediatr
1993;122:647.
136. Lovell D, Giannini E, Brewer E. Time course of response to nonsteroidal
anti-inflammatory drugs in patients with juvenile rheumatoid arthritis.
Arthritis Rheum
1984;27:1433.
137. Skeith KJ, Jamali F. Clinical pharmacokinetics of drugs used in juvenile
arthritis.
Clin Pharmacokinet
1991;21(2):129–149.
138. Giannini E, Cawkwell G. Drug treatment in children with juvenile
rheumatoid arthritis. Past, present, and future.
Pediatr Clin North Am
1995;42:1099.
139. Huppertz H, Tschammler A, Horwitz A. Intraarticular corticosteroids
for chronic arthritis in children: efficacy and effects on cartilage and
growth.
J Pediatr
1995;127:317.
140. Padeh S, Passwell J. Intraarticular corticosteroid injection in the manage-
ment of children with chronic arthritis.
Arthritis Rheum
1998;41:1210.
141. Beukelman T, Guevara JP, Albert DA. Optimal treatment of knee mon-
arthritis in juvenile idiopathic arthritis: a decision analysis.
Arthritis
Rheum
2008;59(11):1580–1588.
142. Sherry DD, et al. Prevention of leg length discrepancy in young chil-
dren with pauciarticular juvenile rheumatoid arthritis by treatment with
intraarticular steroids.
Arthritis Rheum
1999;42(11):2330–2334.
143. Giannini EH, et al. Methotrexate in resistant juvenile rheumatoid arthritis.
Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The
Pediatric Rheumatology Collaborative Study Group and The Cooperative
Children’s Study Group.
N Engl J Med
1992;326(16):1043–1049.
144. Woo P, et al. Randomized, placebo-controlled, crossover trial of low-
dose oral methotrexate in children with extended oligoarticular or sys-
temic arthritis.
Arthritis Rheum
2000;43(8):1849–1857.
145. Ruperto N, et al. A randomized trial of parenteral methotrexate compar-
ing an intermediate dose with a higher dose in children with juvenile
idiopathic arthritis who failed to respond to standard doses of metho-
trexate.
Arthritis Rheum
2004;50(7):2191–2201.
146. Wallace CA, Sherry DD. Preliminary report of higher dose metho-
trexate treatment in juvenile rheumatoid arthritis.
J Rheumatol
1992;
19(10):1604–1607.
147. Lovell DJ, et al. Etanercept in children with polyarticular juvenile rheu-
matoid arthritis. Pediatric Rheumatology Collaborative Study Group.
N Engl J Med
2000;342(11):763–769.
148. Lovell D, Giannini E, Reiff A. Long-term efficacy and safety of etaner-
cept in children with polyarticular-course juvenile rheumatoid arthritis:
interim results from an ongoing multicenter, open-label, extended treat-
ment trial.
Arthritis Rheum
2003;48(1):218.
149. Lovell DJ, et al. Safety and efficacy of up to eight years of continu-
ous etanercept therapy in patients with juvenile rheumatoid arthritis.
Arthritis Rheum
2008;58(5):1496–1504.
150. Gerloni V, Lurati A, Gattinara M. Efficacy of infusions of an anti
TNF-
a
antibody (infliximab) in persistently active refractory juvenile
idiopathic arthritis. Results of a two years open label prospective study.
Arthritis Rheum
2003;48(9):S92.
151. Ardoin S, Rabinovich E, Jaffe G. Infliximab to treat pediatric chronic
inflammatory uveitis.
Arthritis Rheum
2003;48(9):S93.
152. Burmester GR, et al. Adalimumab alone and in combination with
disease-modifying antirheumatic drugs for the treatment of rheumatoid
arthritis in clinical practice: the Research in Active Rheumatoid Arthritis
(ReAct) trial.
Ann Rheum Dis
2007;66(6):732–739.
153. Lovell DJ, et al. Adalimumab with or without methotrexate in juvenile
rheumatoid arthritis.
N Engl J Med
2008;359(8):810–820.
154. Foeldvari I, et al. Tumor necrosis factor-alpha blocker in treatment of juve-
nile idiopathic arthritis-associated uveitis refractory to second-line agents:
results of a multinational survey.
J Rheumatol
2007;34(5):1146–1150.
155. Wallis R, Broder M, Wong J. Granulomatous infectious diseases associ-
ated with tumor necrosis factor antagonists.
Clin Infect Dis
2004;38:1261.
156. Van Rossum MA, Fiselier T, Franssen M. Sulfasalazine in the treatment
of juvenile chronic arthritis: a randomized, double-blind, placebo-
controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study
Group.
Arthritis Rheum
1998;41:808.
157. Ansell B, Hall M, Loftus J. A multicenter pilot study of sulphasalazine
in juvenile chronic arthritis.
Clin Exp Rheumatol
1991;9:201.
158. Hertzberger-ten Cate R, Cats A. Toxicity of sulfasalazine in systemic
juvenile chronic arthritis.
Clin Exp Rheumatol
1991;9:85.
159. van Rossum MA, et al. Sulfasalazine in the treatment of juvenile chronic
arthritis: a randomized, double-blind, placebo-controlled, multicenter
study. Dutch Juvenile Chronic Arthritis Study Group.
Arthritis Rheum
1998;41(5):808–816.
160. Genovese MC, et al. Abatacept for rheumatoid arthritis refractory to
tumor necrosis factor alpha inhibition.
N Engl J Med
2005;353(11):
1114–1123.
161. Ruperto N, et al. Abatacept in children with juvenile idiopathic arthritis:
a randomised, double-blind, placebo-controlled withdrawal trial.
Lancet
2008;372(9636):383–391.
